The most recent phase of the clinical trial was designed to evaluate the effectiveness of the ATS 3f Enable Aortic Bioprostheses ‘sutureless’ solution with respect to hemodynamics, avoiding
The NEwArT study is a Phase IV, open-label, randomized, multicenter trial with a primary endpoint of virologic response at 48 weeks, defined as a viral load
Combined with existing cash and commitments, the additional funds raised in this round will allow F-star to further speed up the development of its unique modular antibody technology
The 300-patient trial will evaluate the Tantalus, an implantable device that delivers electrical pulses to the stomach when a person eats. The primary objective of the randomized, double-blind
Through this agreement, Green Cross will pay a royalty on net sales of Abraxane in Korea as well as upfront and milestone payments. Green Cross will employ an
The Phase I study will assess the safety and pharmacokinetics of single injections of PEG-PAL (poly ethylene glycol-phenylalanine ammonia lyase) in approximately 35 phenylketonuria (PKU) patients in a
Pronova BioPharma said that it strongly opposes this decision and will appeal the ruling, a process which is expected to last for several years. The patent in suit
Accordingly, Urigen has acquired worldwide rights to develop and commercialize intra-nasal testosterone. In exchange, Mattern will receive an undisclosed up-front number of Urigen common shares and will receive
The alliance is anchored around Fovea’s proprietary high content technology platform that allows the identification of new targets involved in photoreceptor degeneration in retinal dystrophies. Both companies declined
This acceptance indicates that all administrative issues have been addressed and that the formal technical evaluation of the application will be conducted under the EMEA’s exceptional circumstances approval
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.